BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32039016)

  • 1. Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78.
    Borjan B; Kern J; Steiner N; Gunsilius E; Wolf D; Untergasser G
    Front Oncol; 2019; 9():1530. PubMed ID: 32039016
    [No Abstract]   [Full Text] [Related]  

  • 2. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
    Ri M
    Int J Hematol; 2016 Sep; 104(3):273-80. PubMed ID: 27169614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GRP78 inhibitor HA15 increases the effect of Bortezomib on eradicating multiple myeloma cells through triggering endoplasmic reticulum stress.
    Chen Y; Tao Y; Hu K; Lu J
    Heliyon; 2023 Sep; 9(9):e19806. PubMed ID: 37809599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
    Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
    Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
    Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
    Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.
    Zaal EA; Wu W; Jansen G; Zweegman S; Cloos J; Berkers CR
    Cancer Metab; 2017; 5():7. PubMed ID: 28855983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
    Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
    Tibullo D; Giallongo C; Romano A; Vicario N; Barbato A; Puglisi F; Parenti R; Amorini AM; Wissam Saab M; Tavazzi B; Mangione R; Brundo MV; Lazzarino G; Palumbo GA; Volti GL; Raimondo FD; Lazzarino G
    Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
    Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
    Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy].
    Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
    Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
    Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
    Wu YX; Yang JH; Saitsu H
    Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
    Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
    Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3.
    Bao L; Wang Y; Lu M; Shi L; Chu B; Gao S
    Biochim Biophys Acta Gen Subj; 2023 Mar; 1867(3):130299. PubMed ID: 36565997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.